Skip to main content
Signal8

Zura Bio Ltd (ZURA)

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Zura Bio Limited logo

Zura Bio Limited

NASDAQ:ZURAHealthcare
AH-0.48%$1.03
Close$1.03-4.17%
Mkt Cap$99.7M
EV-$9.71M
Float68.65M
O/S96.33M
VOL3.52M sh
$ Vol$3.58M
RVOL0.47×
Inst Own71.9%
Net Cash/Sh+$1.14
EarningsMar 31 · in 4mo
Dilution
Zura Bio Limited logoNASDAQ:ZURAAH$1.03-0.48%
Financials Summary
Revenue$0
Net Income-$68.65M
Total Assets$113.95M
Free Cash Flow-$64.93M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$101.54M
Shares Outstanding
Short Interest

No short interest data available.

Split History

No splits on record

Nothing in ZURA's public trading history: no forward or reverse split has affected the share count.

Balance Sheet Details
Assets$113.95M
Liabilities$12.41M
Accounts Receivable$0
Accounts Payable$1.28M
Inventory$0
PP&E (Net)$126K
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue$0$0$0$0$0
YoY Growth-----
Cost of Revenue$0$0$0$0$0
Gross Profit$0$0$0$0$0
Gross Margin-----
Research and Development$42.08M$24.4M$44M$23.69M$0
Selling, General, and Administrative$33.16M$30.79M$18.64M$3.47M$1.09M
Other$0$0$0$0$0
Total Operating Expenses$75.25M$55.19M$62.64M$27.16M$1.09M
Operating Income (EBIT)-$75.25M-$55.19M-$62.64M-$27.16M-$1.09M
Operating Margin-----
Interest Expense$0$0$0$0$0
Interest Income$6.34M$8M$2.19M$570$23K
Other Income (Expense)$6.6M$2.79M$2.08M-$171K$9.51M
Income Before Tax (EBT)-$68.65M-$52.4M-$60.56M-$27.33M$8.42M
Income Tax Expense$0$0$0$0$0
Net Income-$68.65M-$52.4M-$60.36M-$25.74M$8.42M
Net Income Margin-----
Supplementary Data
EPS-1.06-0.60-2.09-1.880.40
Diluted EPS-1.06-0.60-2.09-1.880.40
Weighted Average OS94.16M75.07M33.06M17.25M17.25M
EBITDA-$68.6M-$52.39M-$60.56M-$27.33M$8.42M
EBITDA Margin-----
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022
CurrencyUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-31
Assets
Current Assets
Cash and Cash Equivalents$109.41M$176.5M$99.81M$1.57M
Short-Term Investments$0$0$0$0
Cash and Short-Term Investments$109.41M$176.5M$99.81M$1.57M
Accounts Receivable$0$0$0$0
Inventory$0$0$0$0
Other Current Assets$2.9M$2.25M$1.04M$189K
Total Current Assets$112.31M$178.74M$100.84M$1.78M
Long-Term Assets
Property, Plant & Equipment Net$126K$91K$0$0
Goodwill$0$0$0$0
Intangible Assets$0$0$0$0
Long-Term Investments$0$0$0$0
Deferred Tax Assets$0$0$0$0
Other Long-Term Assets$1.51M$698K$0$3.49M
Total Long-Term Assets$1.64M$789K$0$3.49M
Other Assets$0$0$0$0
Total Assets$113.95M$179.53M$100.84M$5.26M
Liabilities
Current Liabilities
Accounts Payable$1.28M$733K$2.75M$2.01M
Short-Term Debt$0$0$0$7.76M
Current Income Tax Payable$0$0$0$0
Current Unearned Revenue$0$0$0$0
Other Current Liabilities$3.32M$1.71M$1.2M$2.77M
Total Current Liabilities$12.41M$19.51M$20.3M$14.82M
Long-Term Liabilities
Long-Term Debt$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0
Other Long-Term Liabilities$0$0$990K$12.5M
Total Long-Term Liabilities$0$0$990K$12.5M
Other Liabilities$0$0$0$0
Total Liabilities$12.41M$19.51M$21.29M$27.32M
Stockholders' Equity
Preferred Stock$0$0$0$0
Common Stock$7K$7K$4K$0
Retained Earnings-$224.55M-$155.9M-$103.49M-$32.06M
Comprehensive Income & Other$0$0$0$0
Other Stockholders' Equity$326.08M$302.7M$162.82M$0
Total Equity$101.54M$146.81M$59.33M-$32.06M
Minority Interest$0$13.2M$20.22M$10M
Total Liabilities and Equity$113.95M$166.33M$80.62M-$4.74M
Supplementary Data
Total Debt$0$0$0$7.76M
Net Debt-$109.41M-$176.5M-$99.81M$6.19M
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021
CurrencyUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating Activities
Net Income-$68.65M-$52.4M-$60.56M-$27.33M$8.42M
Depreciation & Amortization$49K$9K$0$0$0
Deferred Income Tax$0$0$0$0$0
Stock-Based Compensation$12.33M$16.8M$9.65M$334K$0
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$3K
  Inventory$0$0$0$0$0
  Accounts Payable-$2.16M$4.21M$0$288K$0
  Other Working Capital-$1.47M-$1.91M$5.12M$3.25M-$238K
Total Working Capital Change-$3.63M$2.31M$5.12M$3.54M-$236K
Other Non-Cash Items-$4.91M$5.21M$30.74M$22.26M-$9.28M
Net Cash from Operating-$64.81M-$28.08M-$15.05M-$1.2M-$1.1M
Investing Activities
Capital Expenditures-$113K-$75K-$8M-$12M$0
Acquisitions$0$0$0$0$0
Purchases of Investments$0$0$0$0-$139.38M
Sales of Investments$0$0$0$0$0
Other Investing Activities$0-$5M$0$0$0
Net Cash from Investing-$113K-$5.08M-$8M-$12M-$139.38M
Financing Activities
Debt Repaid--$10M--
Common Stock Issuance$5.2M$60.76M$116.41M$0$140.82M
Common Stock Repurchases$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing Activities-$7.37M$49.09M$14.89M-$2.83M$505K
Net Cash from Financing-$2.16M$109.84M$121.29M$14.77M$141.21M
Forex Effect$0$0$0$0$0
Net Change in Cash-$67.09M$76.69M$98.24M$1.57M$729K
Supplementary Data
Operating Cash Flow-$64.81M-$28.08M-$15.05M-$1.2M-$1.1M
Capital Expenditure-$113K-$75K-$8-$12-$4
Free Cash Flow-$64.93M-$28.15M-$23.05M-$13.2M-$1.1M
Cash at Beginning$176.5M$99.81M$1.57M$0$0
Cash at End$109.41M$176.5M$99.81M$1.57M$729K